The Pink Sheet: US Retail Drug Spending Growth Slows Substantially In 2016
December 07, 2017
PCMA President Mark Merritt said “despite the noise around drug prices, PBMs are doing a pretty solid job reducing costs...
The Pink Sheet: US Retail Drug Spending Growth Slows Substantially In 2016
December 07, 2017
PCMA President Mark Merritt said “despite the noise around drug prices, PBMs are doing a pretty solid job reducing costs...
The Pharma Letter: Drugmakers and middlemen fight over who’s to blame for high US prices
December 01, 2017
PCMA said that the evidence showed drugmakers determine list prices independently of any rebates they negotiate with PBMs...
The Washington Post: The Trump administration is taking on drug prices – but not drug companies
November 24, 2017
The PCMA cited federal government data to argue that providing rebates to patients at the pharmacy counter would drive up...
Fierce Pharma: Medicare Part D rule change would be another win for pharma’s lobbyists, analyst says
November 21, 2017
PCMA said a change to force insurance plans to “estimate and apply” manufacturer rebates at the point of sale would...
Stat News: Trump proposal to lower drug prices targets insurer, PBM rebates
November 20, 2017
PCMA said the proposal could “create a windfall for drugmakers,” who would be on the hook for fewer of the...
Bloomberg: Trump Weighs Medicare Plan to Cut Out-of-Pocket Costs for Drugs
November 20, 2017
PCMA, which represents PBMs, said such a policy would raise taxpayer costs as well as plan premiums by tens of...
The Pink Sheet: Medicare May Require Part D Plans To Provide Point-of-Sale Rebates
November 20, 2017
PCMA challenged the point-of-sale rebate idea, noting it would “raise premiums by up to $28 billion and taxpayer costs by...
November 14, 2017
Companies providing prescription drug coverage hire PBMs for their expertise, and ability to reduce drug costs...
Washington Business Journal: There’s a solution to soaring drug prices
November 09, 2017
Consumers are often left to wonder: Who is fighting on their behalf? The answer: pharmacy benefit managers, or PBMs...
The Pink Sheet: The Great Rebate Debate: Why Do They Exist?
October 27, 2017
Mark Merritt came into the hearing with a much more straightforward message: PBMs want the lowest net cost and don’t...
BioPharma Dive: In Congressional spotlight, drug industry groups blame each other
October 18, 2017
There’s no correlation between manufacturer price increases and the rebates and discounts they negotiate with PBMs”...
October 18, 2017
“There’s no correlation between manufacturer price increases and the rebates and discounts they negotiate with PBMs,” said Mark Merritt...